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The intestinal uptake of paclitaxel is hampered by trans-membrane efflux transporters such
as P-glycoprotein (P-gp), and paclitaxel is mainly metabolized by cytochrome P450 3A4
(CYP3A4) presented in the liver. Our previous results demonstrated that flavonoids extracted
from Taxus yunnanensis could improve the oral absorption of paclitaxel. The current study
was purposed to investigate the effects of the flavonoid extracts on P-gp andCYP3A4 in vitro.
The expression and activity of P-gp were detected by western blotting and intracellular
rhodamine 123 accumulation assay in Caco-2 cells treated with the flavonoids extract. The
expression of CYP3A4 was investigated by western blotting in mouse primary hepatocytes
and the activity of CYP3A4 was detected by LC-MS/MS method using rat liver microsomes.
Our results showed that the flavonoid extracts from T. yunnanensis could inhibit P-gp activity
and concurrently decrease the expression and activity of CYP3A4. In conclusion, activity of
P-gp andCYP3A4 could be inhibited by flavonoids extracted from T. yunnanensiswhichmight
be potential candidates for development of oral formulation of paclitaxel.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction infusion because its intestinal uptake is avidly hampered byPaclitaxel was derived from the bark of the pacific yew tree
(Taxus brevifolia) and worldwide used as one of the most
important anticancer drugs for the treatment of various tu-
mors such as breast, ovarian and lung cancer [1,2]. Until
recently, paclitaxel is clinically formulated in a mixture of
Cremophor EL and dehydrated ethanol for the intravenous; fax: þ86 20 39943000.
(M. Huang).
g Pharmaceutical Univer
sevier
ang Pharmaceutical Univtransmembrane efflux transporter suchas P-glycoprotein [3,4].
Since Cremophor EL itself could be toxic and the oral admin-
istration has many advantages over intravenous admin-
istration, oral paclitaxel formulation is still needed as a critical
option for treating cancer [5]. Oral paclitaxel formulas
have been tried for decades, including concomitant use of
P-glycoprotein inhibitors, such as verapamil, tamoxifen,sity
ersity. Production and hosting by Elsevier B.V. All rights reserved.
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olized by the liver, several studies have demonstrated that co-
administration of CYP3A4 inhibitors could enhance the oral
bioavailability of paclitaxel [9,10]. However, no oral formula of
paclitaxel has been approved by far. The use of those drugs is
limited because the required concentrations to modulate P-gp
and CYP3A could result in cardiac toxicity and other adverse
effects [11]. Therefore, compounds that can inhibit P-gp and
CYP3A4activitywith low toxicity arehighly desired to increase
the systemic exposure of paclitaxel.
Taxus yunnanensis Cheng et L.K. Fu, which belongs to the
plant family Taxaceae is widely distributed in south China.
The branches, leaves and seeds of this plant have been used in
traditional Chinese medicine for the treatment of kidney
problem and diabetic conditions. In recent years, T. yunna-
nensis has been exploited a lot for its high content of pacli-
taxel. Meanwhile, many other components except for
paclitaxel found in T. yunnanensis were shown biological ac-
tivities [12,13].
Our previous pharmacokinetic results showed that oral
bioavailability of paclitaxel was elevated by 10 times while the
whole extract derived from T. yunnanensis containing pacli-
taxel was orally administrated to rats. Interestingly, flavonoid
extract derived from T. yunnanensis was further confirmed to
improve the oral bioavailability of paclitaxel (Data not show).
According to our previous studies, flavonoids derived from T.
yunnanensis might exert synergistic effect on paxlitaxel by
affecting its pharmacokinetic behavior. However, the under-
lying mechanism is unclear yet. Many natural products have
been widely reported to be able to increase the systemic
exposure of paclitaxel by inhibiting the activity of P-glyco-
protein and/or CYP3A [14e16]. Therefore, in this study, we
investigated the effect of flavonoids derived from T. yunna-
nensis on P-gp and CYP3A4 to understand whether the flavo-
noids extract increased the systemic exposure of paclitaxel by
inhibiting P-gp and/or CYP3A4.2. Materials and methods
2.1. Materials
Barks and leaves of T. yunnanensis Cheng et L.K. Fu was sup-
ported by Zhongda Nanyao Co Ltd. Male SpragueeDawley rats
(weighing about 270e300 g) and C57 mice (weighing about
20e25 g) were obtained from the Experimental Animal Center
of Sun Yat-sen University. DMEM (Dulbecco’s Modified Eagle’s
medium) was obtained from HyClone. HBSS, PBS were ob-
tained from GIBCO. Penicillin and streptomycin were from
North China pharmaceutical Group Corporation. NADPH was
obtained from Roche Diagnostics Ltd (Beijing, China). Trizol
reagent, the Williams’ medium E, fetal bovine serum and L-
glutamine were purchased from Invitrogen (Carlsbad, CA).
BSA was from Sangon Biotech (Shanghai) Co. Ltd. Antibodies
of rabbit anti-mouse cyp3a11 and horseradish peroxidase-
labeled anti-goat IgG were obtained from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). Methanol and Tert-Butyl
methyl ether of high performance liquid chromatography
(HPLC) grade were purchased from Tedia Inc. (Beijing, China).
All other reagents were of analytical grade or HPLC grade.2.2. Extraction, isolation and analysis of flavonoids
Dried and pulverized barks and leaves of T. yunnanensis Cheng et
L.K. Fu were extracted in back streaming apparatus with petro-
leum ether (b.p. 61 C) and 70% ethanol/water for 3 times. The
ethanol/water extract was concentrated and dried in the evapo-
rator. Flavonoids were chromatographed over Sephadex LH-20
column with ethanol and determined by HPLC-UV and UV.
Chromatographic fingerprint analysis of flavonoids was per-
formed on Shimadzu LC-20 UFLC system (Shimadzu, Tokyo,
Japan)equippedwithanLC-20ADpump,aSIL-20Aautosampler,a
CTO-20A oven and an SPD-M20A detector. The separation and
analysis of flavonoids was performed on a C18 Column
(250 mm  2.1 mm, 5 mm, Gemini, Phenomenex, USA) kept at
25 C.Themobilephaseswasconsistedofmethanol (A)andwater
(B) as following gradient programsat 1.0ml/min: 0e30min (30%e
60% A), 30e40 min (60%e80% A), 40e60 min (80% A), 60e65 min
(80e100% A), 65e75 min (100% B), 75e80 min (100%e30% A),
80e90 min (30%). The eluent was monitored at wavelength of
190e600 nm. The injection volume for all samples was 20 ml.
2.3. Cell culture
Caco-2 cells were obtained from the American Type Culture
Collection (Manassas, VA, USA). The cells were cultured in H-
DMEM containing 10% FBS in a humidified atmosphere of 5%
CO2 at 37 C [17].
2.4. Isolation and culture of primary hepatocytes
The primary hepatocytes were isolated from C57 mice, which
were supplied by the Laboratory Animal Service Center at Sun
Yat-sen University (Guangzhou, China). Mouse was injected
with 5 ml/g 0.7% chloralic hydras, and hepatic portal vein was
perfused at 5 ml/min speed with digestion buffer to get
excised liver. Then liver was cut up in the wash buffer and got
through 100  mesh sheet. Hepatocytes were obtained after
spinning 600 r/min and seeded into 12-well plates. The cells
were cultured with daily change of media (Williams’ E me-
dium supplemented with L-glutamine, and fetal bovine
serum), after 48 h, the hepatocytes were treated with media
containing the test chemicals [18].
2.5. Detection of expression of P-gp and CYP3A4 by
western blotting analysis
P-gp expression was evaluated by western blot analysis in
Caco-2 cells cultured for 48 h in presence or in absence of the
flavonoid compounds. Caco-2 cells were digested in 0.25%
trypsin and lysed for protein extraction. Protein concentra-
tions of cells were determined using the lowry method [19]
and bovine serum albumin as a standard. The protein sam-
ple (30 mg) was separated in 10% (w/v) SDS e polyacrylamide
gel and blotted into a nitrocellulose membrane (Immobilon
transfer membrane) at 250 mA for 90 min. The membranes
were blocked for 2 h at room temperature in TBST containing
5% non-fat milk and then were incubated with P-gp antibody
(1:500) or GAPDH (1:1000) overnight. Membranes were incu-
batedwith secondary antibody for 2 h. The protein bandswere
obtained from Gel image system. The expression of P-gp was
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 1 6 8e1 7 3170normalized by that of GADPH. Cyp3a11 (CYP3A4 in human)
expression was evaluated using mouse primary liver cell and
incubated with anti-cyp3a11 antibody.2.6. Effect of flavonoids on P-gp activity
Caco-2 cells were incubated in 37 C, 5% CO2 flask for 1 week,
and were further seeded into 96-well black plate with clear
bottom at a density of 10,000 cells per well for 2 days. Then
cells were treated with cyclosporine A (the positive control,
10 mM), vehicle (0.1% DMSO) and flavonoid components in
three groups at concentrations of 0.5 mg/ml, 5 mg/ml and 50 mg/
ml for 1 h or 48 h. Rhodamine 123 (10 mM) and MK571 (MRP
inhibitor, 50 mM) was added. After 1 h, cells were kept on ice to
stop P-gp activity and washed twice with ice-cold Hanks to
remove extra cellular rhodamine 123. A total of 200 ml Hanks
was added and fluorescence of intercellular rhodamine 123
was scanned by a CytoFlour fluorescence multiwall plate
reader at an excitation wavelength of 485 nm and an emission
wavelength of 535 nm [20].2.7. Preparation of rat liver microsomes
Hepatic tissues were collected from healthy male Spra-
gueeDawley rats (230e310 g). Liver microsomes were prepared
as described previously, resuspended in 0.125 M KCl/0.01 M po-
tassiumphosphate,storedat80 C,andusedinonemonth [21].2.8. Effect of flavonoids on CYP3A4 activity
The liver microsomes (0.25 mg/ml) were incubated in pres-
ence or in absence of the flavonoid compounds at different
concentrations for 30 min, midazolam (MDZ) was added and
after 15 min tert-butyl methyl ether/dichloromethane (75:25,
v/v) was added to stop metabolism of MDZ. CYP3A4 activity
was evaluated by amount of the metabolite of MDZ: 1-OH-
midazolam (1-OH-MDZ), which was detected by liquid chro-
matography/tandem mass spectrometry [22].Fig. 1 e HDS extracts in 227 nm (characteristic wavelength for fl
methylamentoflavone, 4. ginkgetin, 5. sciadopitysin.2.9. Transient transfection and reporter gene assay
LS174T cells were seeded into 96-well plate and cultivated for
24 h. Transfection was performed in Phenol red-free RPMI
1640 medium supplemented with charcoal/dextran-treated
FBS. The cells were transfected with 100 ng PSG5-PXR,
100 ng PGL3-CYP3A4-XREM-reporter, 5 ng PLR-TK as an in-
ternal control. 50 ng PSG5 was transfected instead of PSG5-
PXR as vector control. After 6 h, cells were exposed to RIF at
10 mm, which is a known PXR transactivator, KTZ (25 mm, the
positive control), and flavonoids at different concentrations
(0.8, 4, 20, 100 mg/ml) for 24 h, the cells were harvested and
analyzed for luciferase expression with a dual-luciferase re-
porter assay kit (Promega) [23].3. Results and discussion
3.1. Polychemistry analysis of extracts
The flavonoid extracts were obtained through fractionation of
ethanol extract of T. yunnanensis using macroporous absor-
bent resin chromatography and HPLC analysis. As shown in
Fig. 1, chromatographic fingerprint analysis of flavonoids
contained amentoflavone, bilobetin, 7-O-methylamento-
flavone, ginkgetin, sciadopitysin.3.2. Effects of flavonoids derived from T. yunnanensis
on P-gp
Western bolt analysis was performed to observe the effect of
flavonoid extracts on the expressionof P-gp.As shown in Fig. 2,
expression of P-gpwas only inhibited slightly as concentration
of flavonoids was up to 50 mg/ml. Furthermore, intracellular
rhodamine 123 accumulation assay was conducted using
Caco-2 cells to investigate the effect of flavonoids on the ac-
tivity of P-gp. Inhibition of P-gp activity leads to decrease of the
efflux of intracellular rhodamine 123 and increase of fluores-
cence associated with intracellular rhodamine 123. Afteravonoids): 1. amentoflavone, 2.bilobetin, 3. 7-O-
Fig. 2 e Effect of flavonoids derived from Taxus yunnanensis
on P-gp protein expression.
Fig. 4 e Analysis of the effect of flavonoids extract derived
from Taxus yunnanensis on Cyp3a11 protein expression.
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rhodamine 123 increased to almost 1000 units comparing with
400 units in control group. To further study inhibitory effect of
flavonoids on P-gp activity in long-term, Caco-2 cells were
incubatedwithflavonoids for 48h, the result showedthatmore
rhodamine 123 was accumulated in cells and fluorescence of
intracellular rhodamine 123 increased tomore than 1500 units
at concentration of 50 mg/ml (Fig. 3). Our results indicated that
increase of intracellular rhodamine 123 by flavonoids was
mainly through inhibiting P-gp activity but not protein
expression. Interestingly, it shouldbenoted thateffectsof the5
flavonoids (see in Fig. 1) we identified from the extract on P-gp
arestill unclear, but thiswholeextract showed inhibitoryeffect**
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Fig. 3 e Effect of flavonoids derived from Taxus yunnanensis on
assay.on P-gp activity, which might be a kind of combined effect of
the components in the extract.3.3. Effects of flavonoids derived from T. yunnanensis
on CYP3A4
Cytochrome P450 (CYPs) are theprincipal enzymes for oxidative
metabolism of drugs and other xenobiotics. In human liver
microsomes, CYP3A4 is the most abundant enzyme, and more
than 50% of drugs (including paclitaxel) clinically used are
oxidized by CYP3A4. Therefore, we further studied the effect of
the flavonoid extract on the expression of CYP3A4 (cyp3a11 in
mouse) using mouse primary hepatocytes. Fig. 4 showed that
expression of cyp3a11 was markedly decreased in cells incu-
bated with flavonoid extract for 48 h, and protein expression of
cyp3a11 was reduced in a concentration dependentmanner. To** **
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Fig. 5 e Analysis of the effect of flavonoids derived from
Taxus yunnanensis on CYP3A activity.
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of CYP3A4, 1-OH-midazolam, the metabolite of typical CYP3A4
substrate of midazolam, was measured by our previously re-
ported LC-MS/MS method after incubation with rat liver mi-
crosomes. After treatment with different concentrations of
flavonoid extracts, the activity of CYP3A was dramatically in-
hibited in a concentration-dependent manner (P < 0.01) (Fig. 5).
It has been reported that flavonoid intake could enhance
the bioavailability of some orally administered drugs [24,25].
In our previous studies, the bioavailability of paclitaxel was
significantly enhanced by T. yunnanensis extract. As
mentioned above, paclitaxel is a substrate of P-gp and is
mainly metabolized by hepatic CYP3A, the pharmacokinetic
interaction of paclitaxel may be attributed not only to the
modulation of P-gp but also to CYP3A4. However, sometimes it
is difficult to distinguish between the effect on P-gp or in****
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Fig. 6 e Effect of flavonoidsCYP3A4 in vivo. Our in vitro study showed that flavonoids
extract from T. yunnanensis significantly reduced expression of
CYP3A and concurrently inhibited activity of CYP3A4. In
addition, amentoflavone isolated from Ginkgo biloba has been
reported to show a strong inhibitory effect on CYP3A4 [26], we
supposed that amentoflavone might be the main inhibitory
factor on CYP3A4 in the current flavonoid extract.3.4. Inhibitory effects of flavonoids derived from T.
yunnanensis on CYP3A4 expression through PXR-CYP3A4
pathway
Pregnane X receptor (PXR) is an important determinant of
xenobiotics-induced CYP3A4 expression. To determine whe-
ther inhibition of CYP3A4 protein expressionwas regulated by
PXR pathway, an in vitro PXR activation assay using a lucif-
erase receptor was performed. Flavonoids were tested in the
human PXR reporter gene system at the concentrations
ranging from 0 to 100 mg/ml. As shown in Fig. 6, compared to
the control group, RIF significantly induced CYP3A4 luciferase
activity to 3.34-fold in transiently transfected LS174T cells
(P < 0.01), and the induction by RIF markedly decreased while
the transfected cells were co-treated with flavonoids and RIF.
The result indicated that flavonoids inhibited gene expression
of CYP3A4 through modulation of PXR pathway.4. Conclusion
In the present study, flavonoid extract was derived from T.
yunnanensis andwas investigated to show inhibitory effects on
both P-gp and CYP3A4, and gene expression of CYP3A4 was
modulated through PXR pathway. Since paclitaxel is the
substrate of P-gp and CYP3A4 and it also can be obtained from
T. yunnanensis, our results suggested that flavonoid extract
derived from T. yunnanensismight provide a pharmacokinetic
benefit for development of oral paclitaxel formulation.**
**
0.8 4 20 100
oids (µg/ml)
extract on PXR activity.
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